報價延遲最少15分鐘:2025/01/11 18:00 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
38.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.34/-3.17
|
|
企業價值
2.70B
|
| 資產負債 |
|
每股賬面淨值
13.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
78.59M
|
|
每股收益
0.72
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 18:00 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. |